MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

Primary Open-Angle Glaucoma (POAG) Clinical Trial

Official title:
Prospective, Open, Comparative, Randomized Study of the Efficacy and Safety Evaluation of the Mexidol® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

Status Completed

Clinical Trial Summary

Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.

Clinical Trial Description

Hypothesis: Mexidol® allows to optimize POAG therapy by reducing mitochondrial dysfunction and stabilizing glaucomatous optic neuropathy by improving the functional activity of mitochondria and its energy-producing function ;

Study Design

Related Conditions & MeSH terms

Glaucoma
Glaucoma, Open-Angle
Primary Open-Angle Glaucoma (POAG)

Clinical Trial Details

NCT number	NCT06437639
Study type	Interventional
Source	Pharmasoft
Contact
Status	Completed
Phase	Phase 4
Start date	September 15, 2023
Completion date	February 2, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02565173` - Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma	Phase 3
Not yet recruiting	`NCT05539508` - Role of Peripheral Vision in Scene Perception (PERISCE)
Terminated	`NCT02226094` - Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension	Phase 1/Phase 2
Completed	`NCT03131167` - Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma	Phase 1
Completed	`NCT01917383` - A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma	Phase 2
Completed	`NCT02829996` - Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG	Phase 2